IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN END STAGE RENAL DISEASE (ESRD) PATIENTS
Author(s)
Rubin JL1, Wilson SM1, Golomb J21DaVita Clinical Research, Minneapolis, MN, USA, 2DaVita Rx, San Bruno, CA, USA
OBJECTIVES: In dialysis patients, bone and mineral (phosphorous, calcium) and regulatory hormones (parathyroid hormone (PTH)) become dysregulated, increasing risk of fractures, cardiac events and death. First line treatment is a low phosphorus diet and prescription phosphate binders. We examined the impact of a refill management system (RMS) - which helps patients proactively manage their refills using predictive algorithms and refill reminders for prescriptions - on serum phosphorus, calcium and PTH in patients prescribed phosphate binder monotherapy. METHODS: Data from a large dialysis organization were used to identify dialysis patients prescribed monotherapy phosphate binder between 1/1/2008-9/30/2010 with at least 6 months of follow-up. Patients enrolled in the RMS were 1:1 propensity score matched to patients not enrolled utilizing age, race, gender, dialysis vintage, body mass index, baseline laboratory values (albumin, calcium, Kt/V, phosphorus, PTH, normalized protein catabolic rate), Charlson comorbidity score, and other comorbid conditions commonly associated with ESRD. The matched cohorts were compared on the percent meeting guideline ranges for phosphorus (3.5-5.5 mg/dL), corrected calcium (8.4-9.5 mg/dL) and PTH (150-600 pg/mL). Values were assessed over the 6-months following the first phosphate binder prescription. Differences between groups were tested using chi-square for proportions. RESULTS: 3,247 RMS patients met the inclusion criteria and were matched 1:1 to a cohort of non-RMS patients. There were no significant differences between the groups on any baseline variables. Patients enrolled in the RMS were more likely to be in target range over the 6 month period on all 3 measures: phosphorus (58.0% vs 55.1%); corrected calcium (74.3% vs. 69.1%) and PTH (80.5% vs. 77.2%), compared to propensity matched controls. All differences were significant at the p<0.05 level. CONCLUSIONS: Results indicate that participation in a pharmacy RMS is associated better laboratory outcomes for dialysis patients.
Conference/Value in Health Info
2011-05, ISPOR 2011, Baltimore, MD, USA
Value in Health, Vol. 14, No. 3 (May 2011)
Code
DM1
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Hospital and Clinical Practices
Disease
Urinary/Kidney Disorders